The global DNA methylation market size is expected to reach USD 4.22 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 14.67% from 2022 to 2030, due to the increased usage of DNA methylation in sequencing analysis. The increased adoption of DNA methylation in the agrigenomics field remains a promising driver of this growth.
In January 2020, a research journal published in Springer stated that DNA methylation and expression analysis shows peanut foliar disease resistance genes have epialleles. DNA methylation analysis continues to open new doors of opportunities for researchers, and pharmaceutical companies. Increased research and developments in this field would further drive the DNA methylation industry in the coming years.
Furthermore, the growing prevalence of esophageal adenocarcinoma has contributed to the overall growth. According to the data published by the American Cancer Society (ACS), in 2022, an estimated 20,640 esophageal cancer cases were undiagnosed in the U.S. The chronic disease. resulted in 16,410 deaths.
Growing esophageal cancer cases in the U.S. highlight the urgent need for early intervention measures that can help improve the low survival rates for patients. In October 2022, a research article published by Fred Hutchinson Cancer Center stated that methylated DNA biomarkers could be used for the detection of esophageal adenocarcinoma and high-grade dysplasia.
The significant increase in the adoption of epigenetics-based treatment strategies, coupled with the broad nucleic acid-based diagnostic tests & kits commercialization is projected to drive the growth of the market. In May 2022, an article published in PubMed stated that theepigenetics-based treatment strategies are to be used for studying Alzheimer’s disease. However, a lack of expertise to perform DNA methylation experiments could restrict the growth. DNA methylation holds significant potential in various biotechnology applications, while the relatively low number of skilled professionals remains an obstacle to growth.
Key players operating in the market are taking several initiatives such as new product developments, entering into a strategic alliance, and regional expansion among others. For instance, in May 2022, Oxford Nanopore announced integrating Remora, a technique that offers accurate and real-time epigenetic insights with nanopore sequencing software. This would further offer simple access to accurate whole genome methylation detection. Similarly, in June 2020, Base Genomics announced of advancing and developing its DNA methylation technology. the aim is to sequence a large amount of epigenetic data from a blood test which could revolutionize the preventative medicine arena.
Request a free sample copy or view report summary: DNA Methylation Market Report
The overall growth is attributed to the growing adoption of DNA methylation in sequencing analysis in the molecular biology and genomics and agrigenomics fields
By technology, the sequencing segment captured the highest share in 2021, owing to the increasing adoption of sequencing technology for research purposes by numerous market players
By product, the consumables segment dominated the market as it is majorly used in the DNA sequencing procedures and diagnosis process
By application, the clinical research segment dominated the market due to the rising number of clinical trials for various diseases globally, and constant government support leading to increasing R&D expenditure
By end use, pharmaceutical and biotechnology companies dominated the market, thanks to the increasing usage of high throughput technologies such as NGS by key market players
North America dominated the market in 2021 due to the wide network of manufacturing and R&D facilities. The growing number of product launches, FDA approvals, and the presence of key market players remains a promising driver of growth in this region
Grand View Research has segmented the global DNA methylation market based on technology, product, application, end-use, and region:
DNA Methylation Technology Outlook (Revenue, USD Million, 2018 - 2030)
Polymerase Chain Reaction (PCR)
Microarray
Sequencing
Others
DNA Methylation Product Outlook (Revenue, USD Million, 2018 - 2030)
Consumables
Kits & Reagents
Enzymes
Instruments & Software
DNA Methylation Application Outlook (Revenue, USD Million, 2018 - 2030)
Gene therapy
Clinical Research
Diagnostics
Others
DNA Methylation End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospital & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Research & Academia
DNA Methylation Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
India
Japan
South Korea
Australia
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
List of Key Players of DNA Methylation Market
New England Biolabs
Sysmex Corporation
Abcam plc.
F. Hoffmann-La Roche Ltd.
Diagenode Diagnostics S.A.
Thermo-Fisher Scientific Inc.
Agilent Technologies Inc.
BioRad Laboratories Inc.
Exact Sciences Corporation
QIAGEN N.V.
Active Motif, Inc.
Illumina Inc.
EpiGentek Group Inc.
Pacific Biosciences Inc.
New England Biolabs Inc.
Merck KGaA
Zymo Research Corporation
PerkinElmer Inc.
"The quality of research they have done for us has been excellent..."